Track Sudeep Pharma Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 1.45 %
Low
1,143.7
High
1,257.3
1 Month returns: 18.58 %
Low
917.4
High
1,257.3
1 Year returns: –
3 Year CAGR: –
5 Year CAGR: –
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Sudeep Pharma Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Sudeep Pharma Ltd. Shareholding Pattern
Quarterly breakdown of Sudeep Pharma Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Sudeep Pharma Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Sudeep Pharma Ltd.?
The current share price of Sudeep Pharma Ltd. is ₹ 1,207.60 as of 12 Nov 2026.
What is the market capitalisation of Sudeep Pharma Ltd.?
The market capitalisation of Sudeep Pharma Ltd. stands at ₹ 13,621.60 Cr.
What is the PE ratio of Sudeep Pharma Ltd.?
The Price-to-Earnings (PE) ratio of Sudeep Pharma Ltd. is 72.19 as of the latest trailing twelve months data.
What is the ROE and ROCE of Sudeep Pharma Ltd.?
Sudeep Pharma Ltd. has a Return on Equity (ROE) of 22.44% and a Return on Capital Employed (ROCE) of 23.58% as per the latest financial reports.
What is the 52-week high and low of Sudeep Pharma Ltd.?
The 52-week high of Sudeep Pharma Ltd. is - and the 52-week low is -.
What is the dividend yield of Sudeep Pharma Ltd.?
The dividend yield of Sudeep Pharma Ltd. is 0.12% based on the current market price.
What is the FII and DII holding in Sudeep Pharma Ltd.?
Foreign Institutional Investors (FII) hold 2.93%, Domestic Institutional Investors (DII) hold 8.45% and retail/public investors hold 6.43% of Sudeep Pharma Ltd. shares.
What sector does Sudeep Pharma Ltd. belong to?
Sudeep Pharma Ltd. operates in the Healthcare sector.
What is the beta of Sudeep Pharma Ltd.?
The beta of Sudeep Pharma Ltd. is -, indicating its price volatility relative to the broader market.
What is the RSI of Sudeep Pharma Ltd.?
The 14-day Relative Strength Index (RSI) of Sudeep Pharma Ltd. is 62.38, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.
1,207.60-0.1 (-0.01%)
56.04% since 28 Nov 2025
Sep 2025
Nov 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Promoter
76.15
76.15
76.15
76.15
76.15
76.15
Indian Promoter
76.15
76.15
76.15
76.15
76.15
76.15
Foreign Promoter
-
-
-
-
-
-
Institutions
15.64
15.64
19.27
19.66
17.46
16.98
Mutual Funds / UTI
3.44
3.44
5.67
6.19
5.47
7.43
FI/Bank/Insurance
1.24
1.24
1.06
1.16
1.39
1.02
Govt
-
-
-
-
-
-
FII
1.54
1.54
1.67
1.55
1.81
2.93
Other Institutions
9.42
9.42
10.86
10.76
8.79
5.61
Non-Institution
8.20
8.20
4.58
4.18
6.39
6.87
Bodies Corporate
0.01
0.01
0.52
0.20
0.37
0.44
Others (incl. Retail)
No. of shareholders
8.19
2,17,766
8.19
2,17,766
4.06
43,513
3.98
36,414
6.02
35,485
6.43
40,166
Holdings and Presence
Indices and prominent investors with a stake in this stock.
Fundamental analysis overview of Sudeep Pharma Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Analysts have been raising forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has increased by 2.29% in the last 3 months, indicating earnings momentum
What is Earnings upgrade (3M)?
Not enough data
Strong revenue growth and above median growth of industry
The company delivered strong revenue growth of 28.43% for 12-month ended 30 Sep 2026 and the growth was 14.56 percentage points higher than median growth of industry
What is Sales growth (1Y)?
Median: 13.87
Value 28.43
-28.674019.76
Strong EPS growth and above median growth of industry
The company delivered strong EPS growth of 26.2% for 12-month ended 30 Sep 2026 and the growth was 7.4 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.13 as on 30 Sep 2026 and Debt to Equity decreased marginally by 0.07 in the last 1 year
What is Debt to Equity?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 72.19 indicates that the stock is expensive on a standalone basis and is at a 139.44% premium to industry median P/E
What is P/E Ratio?
Median: 30.15
Value 72.19
-0.82716.27
Low dividend yield
The company has a low dividend yield of 0.12%
What is Dividend yield?
Neutral
High ROE but declining trend
The company reported strong ROE of 22.44% for 12-month ended 30 Sep 2026 but ROE declined by -1023 bps from 1 year ago
What is ROE (FY)?
High operating margin but declining trend
The company reported strong operating margin of 32.92% for 12-month ended 30 Sep 2026 but operating margin declined by -249 bps from 1 year ago
What is Operating profit margin?
Company's earnings are of moderate quality
Earnings quality score of 33.9 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
33.9 / 100
No red flags found!
No significant red flags found in the stock.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Name
Date
Type
Price
Qty.
Value
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES III
24 Jul 2026
sell
₹ 800.00
10.60 lac
₹ 84.80 cr
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIA
24 Jul 2026
sell
₹ 800.00
9.40 lac
₹ 75.20 cr
SBI MUTUAL FUND
24 Jul 2026
buy
₹ 800.00
20.00 lac
₹ 160.00 cr
Corporate Actions
History of Sudeep Pharma Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Dividend₹ 1.50/share
Record date: 23rd Jul 2026Ex-date: 23rd Jul 2026
Announced on: 21st May 2026
Company Profile
Overview of Sudeep Pharma Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Sudeep Pharma Private Limited is an India-based manufacturing pharmaceutical and nutraceutical products company. The Company is engaged in business of manufacturing and selling pharmaceutical and food, nutrition and specialty ingredients and intermediaries, used by pharmaceutical, food and nutrition industries globally. The Company a wide range of products, including mineral salts such as calcium salts, zinc salts, iron salts, potassium salts, magnesium salts, sodium salts, simethicone salts and copper salts. It offers products to a wide range of markets, which includes pharmaceuticals, dietary health, infant nutrition, beverage, dairy products, bakery products, confectionery, and staple food markets. Its subsidiaries include Sudeep Nutrition Private Limited, Sudeep Pharma USA Inc., Sudeep Pharma B.V., and Sudeep Advanced Materials Private Limited.
Sudeep Pharma Private Limited is an India-based manufacturing pharmaceutical and nutraceutical products company. The Company is engaged in business of manufacturing and selling pharmaceutical and food, nutrition and specialty ingredients and intermediaries, used by pharmaceutical, food and nutrition...